The White House issued an Executive Order that directs federal agencies to accelerate the development, review, and potential access to novel treatments for serious mental illness, with a particular focus on certain investigational psychedelic therapies, including but not limited to ibogaine, for treatment resistant conditions such PTSD, depression, and substance use disorder.
The order notes that psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy.
The order directs the FDA to provide National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program; this would facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act, including any necessary Schedule I handling authorizations for treating physicians and researchers.
In response, the FDA announced that they will soon issue national priority vouchers to three companies; one to a company studying psilocybin for treatment-resistant depression, one to a company studying psilocybin for major depressive disorder, and another company studying methylone for PTSD. This action will allow the review of those drugs to be approved quickly – perhaps in just weeks – making this the first time the FDA has offered to fast-track any psychedelics.
Additionally, the Department of Health and Human Services (DHS) shall, through the Advanced Research Projects Agency for Health, allocate at least $50 million from existing funds to support and partner with State governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses, including through Federal funding, technical assistance, and data sharing as appropriate and consistent with applicable law.
The DHS and the FDA will also collaborate with the Department of Veterans Affairs and the private sector to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, and shall prioritize drugs that have received a Breakthrough Therapy designation. Data from relevant clinical studies will be made available to FDA to facilitate the timely evaluation and approval of drugs that meet standards for approval.
This development in particular is noteworthy, as the VA, after decades of resistance to psychedelic therapy, is now participating in at least five drug trials in New York, California, and Oregon.
The order also directs the Attorney General to, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate, may proceed as quickly as practicable for such specific products that are ultimately approved.
This Executive Order signals increased federal interest in nontraditional therapies for treatment‑resistant mental health conditions that may influence future state‑level policy or legislative discussions, even as psychedelics remain federally restricted.
